超低剂量全身18F-FDG PET/CT在自身免疫性炎症性关节炎中的初步观察
本研究前瞻性纳入30例参与者(24例自身免疫性炎症性关节炎、6例骨关节炎),在静脉注射78.1 ± 4.7 MBq 18F-FDG后40分钟起行20分钟全身PET/CT采集。全身PET/CT单床位即可显示全身包括手足关节的18F-FDG摄取;在1997个可评估关节中,自身免疫性炎症性关节炎队列PET定性评估与逐关节风湿学检查的一致率为69.9%,非自身免疫性炎症性关节炎队列为91.1%。作者结论为全身PET/CT超低剂量方案用于系统性关节评估可行,结果为未来更大规模研究奠定基础。
要点
- 全身PET/CT超低剂量方案单床位可显示全身包括手足关节的18F-FDG摄取。
- 自身免疫性炎症性关节炎队列1997个可评估关节中PET与风湿学检查一致率69.9%。
- 非自身免疫性炎症性关节炎队列一致率91.1%,10.0%与0%关节风湿学阳性而PET阴性。
核心结论
- 作者结论认为,采用全身PET/CT系统与超低剂量方案对自身免疫性炎症性关节炎(及非自身免疫性炎症性关节炎)进行系统性关节评估是可行的。
- 作者指出,本研究结果为未来更大规模研究评估全身PET/CT技术可能改善自身免疫性炎症性关节炎关节评估奠定了基础。
研究设计与样本
- 本研究为单中心、观察性研究,前瞻性纳入30例参与者,其中24例自身免疫性炎症性关节炎、6例骨关节炎。
- 所有参与者均在静脉注射78.1 ± 4.7 MBq 18F-FDG后40分钟起行20分钟全身PET/CT扫描。
- 对所得图像进行18F-FDG摄取与关节受累的定性及定量评估,并与风湿学评估进行比较。
主要发现
- 全身PET/CT可在单床位、同一放射性示踪剂摄取时相内显示全身包括手足关节的18F-FDG摄取。
- 图像可见与自身免疫性炎症性关节炎相符的多种病理表现(骨关节炎组为非自身免疫性炎症性关节炎表现),并证明可从风湿学评估所检查的关节提取PET指标。
- 1997个可评估关节中,全身PET定性评估与逐关节风湿学评估的一致率在自身免疫性炎症性关节炎队列为69.9%、非自身免疫性炎症性关节炎队列为91.1%。
- 风湿学检查判定为阴性的关节中,自身免疫性炎症性关节炎队列另有20.1%、非自身免疫性炎症性关节炎队列另有8.8%显示PET阳性。
- 风湿学评估为阳性而全身PET为阴性的关节在自身免疫性炎症性关节炎队列为10.0%、非自身免疫性炎症性关节炎队列为0%。
关键数值与推荐
- 全身PET/CT扫描方案:静脉注射78.1 ± 4.7 MBq 18F-FDG后40分钟开始,采集20分钟。
- 自身免疫性炎症性关节炎队列PET与风湿学评估一致率69.9%,非自身免疫性炎症性关节炎队列91.1%。
- 风湿学阴性而PET阳性关节比例:自身免疫性炎症性关节炎队列20.1%,非自身免疫性炎症性关节炎队列8.8%。
- 风湿学阳性而PET阴性关节比例:自身免疫性炎症性关节炎队列10.0%,非自身免疫性炎症性关节炎队列0%。
- 自身免疫性炎症性关节炎队列全身PET定量指标与风湿学结局指标的Spearman ρ = 0.53-0.70(P < 0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出,本研究结果为未来更大规模研究评估全身PET/CT技术可能改善自身免疫性炎症性关节炎关节评估奠定了基础。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autoimmune inflammatory arthritides (AIA), such as psoriatic arthritis and rheumatoid arthritis, are chronic systemic conditions that affect multiple joints of the body. Recently, total-body (TB) PET/CT scanners exhibiting superior technical characteristics (total-body coverage, geometric sensitivity) that could benefit AIA evaluation, compared with conventional PET/CT systems, have become available. The objectives of this work were to assess the performance of an ultra-low-dose, 18F-FDG TB PET/CT acquisition protocol for evaluating systemic joint involvement in AIA and to report the association of TB PET/CT measures with joint-by-joint rheumatologic examination and standardized rheumatologic outcome measures. Methods: Thirty participants (24 with AIA and 6 with osteoarthritis) were prospectively enrolled in this single-center, observational study. All participants underwent a TB PET/CT scan for 20 min starting at 40 min after intravenous injection of 78.1 ± 4.7 MBq of 18F-FDG. Qualitative and quantitative evaluation of 18F-FDG uptake and joint involvement were performed from the resulting images and compared with the rheumatologic assessments. Results: TB PET/CT enabled the visualization of 18F-FDG uptake at joints of the entire body, including those of the hands and feet, in a single bed position, and in the same phase of radiotracer uptake. A range of pathologies consistent with AIA (and non-AIA in the osteoarthritis group) were visualized, and the feasibility of extracting PET measures from joints examined by rheumatologic assessments was demonstrated. Of 1,997 evaluable joints, there was concordance between TB PET qualitative assessments and joint-by-joint rheumatologic evaluation in the AIA and non-AIA cohorts for 69.9% and 91.1% joints, respectively, and an additional 20.1% and 8.8% joints, respectively, deemed negative on rheumatologic examination showed PET positivity. On the other hand, 10.0% and 0% joints in the AIA and non-AIA cohorts, respectively, were positive on rheumatologic evaluation but negative on TB PET. Quantitative measures from TB PET in the AIA cohort demonstrated a moderate-to-strong correlation (Spearman ρ = 0.53-0.70, P < 0.05) with the rheumatologic outcome measures. Conclusion: Systemic joint evaluation in AIA (and non-AIA) is feasible with a TB PET/CT system and an ultra-low-dose protocol. Our results provide the foundation for future larger studies to evaluate the possible improvements in AIA joint assessment via the TB PET/CT technology.
引用
- Abdelhafez Y, Raychaudhuri SP, Mazza D, et al. Total-Body 18F-FDG PET/CT in Autoimmune Inflammatory Arthritis at Ultra-Low Dose: Initial Observations. J Nucl Med. 2022. PMID: 35589405. doi:10.2967/jnumed.121.263774
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。